For international pharma and biotech companies looking to establish or expand R&D activities in Europe, Denmark has created an ecosystem where neuroscience innovation can move faster and with greater confidence. Research is embedded in clinical practice, trial-ready infrastructure is in place, and national health data assets support smarter development from early research to real-world evidence.

That makes Denmark more than an attractive location for neuroscience innovation. It makes Denmark a strategic partner for companies looking to de-risk development and accelerate progress in one of life science’s most demanding fields.

One of Denmark’s most distinctive advantages is the deep integration of clinical research within its public healthcare system. Universities and hospitals work in close alignment, allowing research to take place directly where patients receive care.

This matters in neuroscience, where successful development depends on close contact between science, clinicians and patients. In Denmark, neurologists and psychiatrists are routinely engaged as principal investigators, helping ensure that studies are clinically relevant and focused on real unmet medical needs. The result is less fragmentation, clearer decision-making and a smoother transition from early clinical research to later-phase trials.

For companies developing therapies in areas such as stroke, epilepsy, Parkinson’s disease, dementia and severe mental illness, this translates into a practical business advantage: 

• predictable timelines 
• strong clinical ownership 
• and high-quality data

Danish neuroscience has long been shaped by collaboration between universities and hospitals. Unlike in markets where basic science and clinical research developed on separate tracks, Danish neuroscience evolved at the intersection of laboratory science and bedside medicine.

That tradition continues today. Neurologists, psychiatrists, neuroscientists and imaging specialists often work side by side within the same institutions, making it easier to tackle complex brain disorders through interdisciplinary collaboration.

This creates a more connected environment for partnerships, translational research and clinical development. It also means that promising discoveries are better positioned to move from insight to impact.

In neuroscience, clinical development can be particularly challenging. Patient recruitment, long-term follow-up and the generation of reliable endpoints often require a highly coordinated setup. Denmark is well equipped to meet that challenge.

The country’s unified healthcare system, comprehensive national health registries and high levels of public trust create ideal conditions for efficient clinical trials and real-world evidence generation. This supports better patient identification, strong retention and robust longitudinal data.

Trial Nation plays a central role here by serving as a single national entry point for companies seeking to initiate clinical trials across Denmark. This coordinated approach gives companies rapid access to leading hospitals, investigators and trial sites, helping make Denmark one of Europe’s most attractive locations for global clinical development.

One example is the Centre for Dementia, which brings together Danish memory clinics with experience in clinical research involving investigational medicinal products in Alzheimer’s disease, Huntington’s disease and other neurodegenerative disorders. The centre supports clinical trials and the application of new medical technology in the diagnosis and treatment of neurodegenerative cognitive disorders.

For pharma and biotech companies, that means fewer headaches and more headway.

Denmark continuously invest in ambitious neuroscience environments designed to strengthen interdisciplinary research and accelerate translation into treatment.

An example is the Danish Neuroscience Center in Aarhus. Backed by foundations, private donors and regional authorities, the new centre is being developed as a landmark facility with the ambition of becoming the first in the world to integrate somatic and psychiatric neuroscience research under one roof.

Strategically located between the psychiatric and neurological departments at Aarhus University Hospital, the centre is designed to bring clinicians, basic scientists and patients closer together. The goal is to speed up the translation of discoveries into real treatments across a wide range of disorders, from dementia and Parkinson’s disease to depression and ADHD.

Another initiative is the Lundbeck Foundation Parkinson’s Disease Research Center, PACE. The centre brings together neurologists, molecular biologists, imaging experts and clinical trial specialists to develop and test new interventions aimed at slowing or stopping the progression of Parkinson’s disease.

Patients play an active role in longitudinal studies, contributing biological samples, imaging data and clinical assessments that feed directly into trial design and therapeutic development. This kind of integrated, patient-centred research is exactly what companies are looking for when evaluating where to place high-value neuroscience activities.

Invest in Denmark helps international pharmaceutical and biotech companies connect with Denmark’s neuroscience ecosystem through tailored and confidential advisory services. We help streamline trial setup, reduce risk and connect companies with the right clinical sites, research partners and experts across the country.